Max Planck Innovation

Max Planck Innovation

Max Planck Innovation is responsible for technology transfer from the Max Planck Society, Germany's leading basic research organization. With the claim “Connecting Science and Business” we perform an important task: the transfer of basic research results into products, which contribute to the economic and social progress. Our interdisciplinary team advises and supports scientists in evaluating their inventions, filing patents and founding companies. We offer industry a unique access to the proprietary innovations of 12.000 scientists conducting research in 80 institutes. Our portfolio comprises innovative technologies from the chemistry, physics and technology section as well as the biology and medicine section.

Contact

Amalienstr. 33
80799 München
Phone: +49 89 29 09 19-0
Fax: +49 89 29 09 19-99
Cellink acquires MPG spin-off Scienion

The company expand its technology portfolio to include precision dispensing technologies

more
Launch of Start-up QLi5 Therapeutics

Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders

more
Cancer drug enters Phase I study

Triple kinase inhibitor increases visibility of tumors to the immune system

more
Corona: vaccination without a needle?

Scientists are developing a procedure whereby vaccines can be absorbed through the skin

more
New approach to curing HIV

New treatment method being tested in clinical study

more

Max Planck Innovation has been the link between science and industry since 1970. The Max Planck Society's technology transfer organization supports researchers in assessing the potential of an invention and applying for patents. In addition, it markets patents, technologies, and know-how to industry and assists founders in setting up companies that translate research results from the Max Planck Society into products and services.

Peter Seeberger has founded nine start-ups to date. With these companies, the Director of the Max Planck Institute of Colloids and Interfaces in Potsdam wants to put the results of his basic research into practice. One goal is to introduce sugar-based vaccines against multi-resistant bacteria.

Katharina Landfester, Director at the Max Planck Institute for Polymer Research in Mainz, has opened the door to numerous applications. She has developed a technology whereby tiny containers can be specifically manufactured for almost any substance and equipped with various functions. Her team is now working on using nanocapsules as transporters for pharmaceuticals, as medical sensors, or as fungus treatments in wine production.

Since the Berlin-based biotech company Scienion was established in 2001, it has experienced its fair share of highs and lows. We talked to its founder about what drives him to succeed and about the typical stumbling blocks and peculiarities associated with spin-offs from basic research.

Evotec’s history illustrates that biotechnology made in Germany can set standards worldwide. The Max Planck Society is one of the company’s founders and continues to shape it to this day.

Founded in 2008, the Lead Discovery Center (LDC) closes the funding gap between basic research and drug development. In this interview, CEO Bert Klebl describes the close cooperation with scientists and the LDC‘s role-model function.

The staff at Max Planck Innovation help turn bold ideas into applications. They assist researchers with licensing negotiations and establishing spin-offs.

No job offers available

Every year, Max Planck Innovation evaluates an average of 120 inventions, with roughly half of these leading to a patent application. Since 1979, approximately 4,450 inventions have been supported and around 2,680 exploitation contracts have been concluded. Since the early 90s, 156 newly founded companies (spin-offs) have emerged from the Max Planck Society. Max Planck Innovation advised the vast majority of them. Over 6,000 jobs have been created in these spin-offs since then. Since 1979, MI has achieved a total turnover from license revenues and divestments of close to 490 million euros.

more

Technology transfer for the institutes of the Max Planck Society

2018 Berninger, Markus

Material Sciences Medicine

Operating under the motto “Connecting Science and Business”, the MPG subsidiary acts as a partner to scientists and business alike. Our interdisciplinary team provides consulting and support for scientists in evaluating inventions, applying for patents, and founding companies. We offer industry a central point of access to the innovations of the Max Planck Institutes. We thus provide the important function of transferring the results of basic research into economically and socially useful products and services.

more

Technology transfer: from the lab to innovative applications

2017 Berninger, Markus

Chemistry Computer Science Medicine

With the claim “Connecting Science and Business.” Max Planck Innovation is partner of both science and industry. Our interdisciplinary team provides consulting and support for scientists in evaluating inventions, applying for patents, and founding companies. We offer industry a central point of access to the innovations of the Max Planck Institutes. We thus provide the important function of transferring the results of basic research into economically and socially useful products and services.

more

Max-Planck-Innovation – technology transfer in the Max Planck Society

2016 Berninger, Markus

Chemistry Computer Science Medicine

With the claim “Connecting Science and Business.” Max Planck Innovation is partner of both science and industry. Our interdisciplinary team provides consulting and support for scientists in evaluating inventions, applying for patents, and founding companies. We offer industry a central point of access to the innovations of the Max Planck Institutes. We thus provide the important function of transferring the results of basic research into economically and socially useful products and services.

more

Technology transfer: Bridging the gap between science and market

2015 Berninger, Markus

Chemistry Computer Science Medicine

As the technology transfer organization of the Max Planck Society, Max Planck Innovation has been connecting science and business since 1970. Our aim is the patenting and marketing of the inventions of more than 80 Max Planck Institutes. Thus we perform an important task: the transfer of basic research results into products which contribute to economic and social progress.

more
Go to Editor View